Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736108 | 0.89 | DRD2 (0.58) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL553304 | 0.86 | PPARG (0.44) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL12324832 | 0.85 | MAPT (0.53) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL16595917 | 0.83 | KDM4E (0.49) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL18089384 | 0.82 | MAPT (0.50) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL4541628 | 0.82 | CA12 (0.53) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL28217693 | 0.82 | MAPT (0.50) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL764370 | 0.82 | MAPT (0.58) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL5778832 | 0.80 | KDM4E (0.60) | MAPTKDM4EGAAALDH1A1LMNA | |
| SCHEMBL31285975 | 0.80 | KDM4E (0.60) | MAPTKDM4EGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491029-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048112-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| EP-1140904-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6800636-B2 | FOR THERAPY OF CANCER | SCHERING CORPORATION | 2004-10-05 | — | — | US | disclosed |
| EP-0807105-B1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | GUZI TIMOTHY (US) | 2003-02-27 | — | — | US | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| US-6194396-B1 | ANTIALLERGENS; ANTIINFLAMMATION AGENTS; AUTOIMMUNE DISEASE; ANTISHOCK AGENTS; ANALGESICS; E.G., A 4 OR 7-PHENYLALKYLENE-OXYBENZIMIDAZOLE UNSUBSTITUTED OR SUBSTITUTED IN THE 1,2,3-POSITION WITH AN OXY, AMINO AND/OR THIO GROUP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| US-6083961-A | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES SUCH AS ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASE, SHOCK, PAIN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-04 | — | — | US | disclosed |
| US-5994368-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| CN-1168667-A | Pyridopyrimidones, quinolines and fused N-heretocycles as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-12-24 | — | — | CN | disclosed |
| EP-0807105-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0774462-A1 | HETEROCYCLIC COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996013485-A1 | PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-05-09 | — | — | WO | disclosed |
| EP-0239927-A1 | Cyclic carbamates | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040520-A1 | Farnesyl protein transferase inhibitors | FNTA, FNTB, CETP | MAPT 2590/4885KDM4E 2712/4885GAA 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.